17-Hydroxyprogesterone caproate
From Wikipedia, the free encyclopedia
 |
|
|
17-Hydroxyprogesterone caproate
|
|
| Systematic (IUPAC) name | |
| [(3S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-acetyloxy- 10,13-dimethyl-1,2,3,8,9,11,12,14,15,16- decahydrocyclopenta[a]phenanthren-3-yl] hexanoate |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C29H42O5 |
| Mol. mass | 470.641 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
17-Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17-hydroxyprogesterone formed from caproic acid (hexanoic acid).
Most progesterones are androgenic at sufficiently high dose and may lead to conditions such as congenital or intrauterine adreno genital syndrome when given in pregnancy especially from 12 to 14 weeks of intrauterine life.[citation needed] 17-Hydroxyprogesterone caproate is the drug of choice if progesterones is required during pregnancy.[citation needed]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
